Danish biopharma company Saniona has a broad drug development pipeline based on ion channel modulators. The company’s focus is on epilepsy, and candidate SAN711 leads the way with phase II evaluation in sights. Now Saniona is carrying out a rights issue of approximately SEK 140 million to drive SAN711 and other projects forward. Saniona’s CEO Thomas Feldthus visited BioStock’s studio to present the company and talk about the latest company updates.
Watch Saniona CEO Thomas Feldthus present the company in the BioStock Investor Pitch below.
This material has been prepared for marketing purposes and is not and shall not be deemed to constitute a prospectus under applicable laws and regulations. The complete terms and conditions of the rights issue and more information about the company have been presented in an issue prospectus that was published on Saniona.com on 18 January 2024.The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.